共 50 条
- [1] Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy [J]. EJSO, 2021, 47 (01): : 60 - 64
- [3] Morbidity of the Abdominal Wall Resection and Reconstruction After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) [J]. Annals of Surgical Oncology, 2015, 22 : 1658 - 1663
- [5] Outcome of Icelandic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) abroad [J]. LAEKNABLADID, 2020, 106 (7-8): : 344 - 348
- [8] Predictors of Financial Toxicity Risk Among Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS–HIPEC) [J]. Annals of Surgical Oncology, 2024, 31 : 1980 - 1989
- [9] Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) [J]. INNOVATIVE SURGICAL SCIENCES, 2024, 9 (01): : 3 - 15